Parcion Private Wealth LLC Sells 3,770 Shares of Pfizer Inc. $PFE

Parcion Private Wealth LLC trimmed its stake in shares of Pfizer Inc. (NYSE:PFE) by 15.8% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,145 shares of the biopharmaceutical company’s stock after selling 3,770 shares during the quarter. Parcion Private Wealth LLC’s holdings in Pfizer were worth $488,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Onyx Bridge Wealth Group LLC lifted its position in Pfizer by 24.3% during the second quarter. Onyx Bridge Wealth Group LLC now owns 39,909 shares of the biopharmaceutical company’s stock worth $967,000 after purchasing an additional 7,813 shares during the period. Steel Grove Capital Advisors LLC raised its stake in Pfizer by 4.7% during the second quarter. Steel Grove Capital Advisors LLC now owns 72,088 shares of the biopharmaceutical company’s stock worth $1,747,000 after acquiring an additional 3,266 shares in the last quarter. Family Capital Management Inc. acquired a new position in Pfizer during the second quarter worth about $742,000. Citizens & Northern Corp increased its stake in shares of Pfizer by 35.0% in the second quarter. Citizens & Northern Corp now owns 49,935 shares of the biopharmaceutical company’s stock valued at $1,210,000 after buying an additional 12,934 shares during the period. Finally, FNY Investment Advisers LLC increased its stake in shares of Pfizer by 61.6% in the second quarter. FNY Investment Advisers LLC now owns 27,324 shares of the biopharmaceutical company’s stock valued at $662,000 after buying an additional 10,414 shares during the period. Institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 0.5%

Shares of Pfizer stock opened at $24.72 on Thursday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The stock has a market capitalization of $140.52 billion, a P/E ratio of 13.15, a P/E/G ratio of 0.82 and a beta of 0.55. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The stock’s 50-day simple moving average is $24.88 and its 200 day simple moving average is $24.13.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 7.0%. Pfizer’s dividend payout ratio is currently 91.49%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. Morgan Stanley decreased their target price on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, October 10th. UBS Group reissued a “neutral” rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday, October 1st. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Finally, Bank of America lifted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.13.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.